Niall Condon, Curia Global's new president of the manufacturing division

Cu­ria nets con­tract for cannabi­noid can­di­date and taps a new pres­i­dent of man­u­fac­tur­ing

The CD­MO Cu­ria, fresh off an ex­pan­sion a year ago, is scal­ing up man­u­fac­tur­ing for a can­di­date from an Aus­tralian biotech.

In­can­nex Health­care, a biotech cen­tered on pro­duc­ing cannabi­noid-based med­i­cines and psy­che­del­ic ther­a­pies, is us­ing Cu­ria Glob­al to fur­ther de­vel­op and man­u­fac­ture a GMP-grade in­haled drug prod­uct for the treat­ment of con­cus­sion and trau­mat­ic brain in­jury orig­i­nal­ly de­vel­oped by the biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.